Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors

Robert T. Eagan; Robert P. Dinapoli; Terrence L. Cascino; Bernd Scheithauer; Brian P. O'Neill; Judith R. O'Fallon

doi:10.1007/BF00148387

Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors

Robert T. Eagan, Robert P. Dinapoli, Terrence L. Cascino, Bernd Scheithauer, Brian P. O'Neill, Judith R. O'Fallon

Neurology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Ninety-three patients with primary intracranial brain tumors recurrent after cerebral irradiation were treated with aziridinylbenzoquinone (AZQ; Diaziquone). Twenty-four (26%) had tumor regression lasting a median of 9.2 months. Prior chemotherapy was not significantly associated with tumor regression but was associated with survival (median 7.3 months no prior chemotherapy versus 4.7 months with prior chemotherapy; logrank p = 0.03). AZQ demonstrated anti-tumor activity in a wide variety of primary intracranial neoplasms recurrent after radiation therapy and deserves study in patients at the time of diagnosis. We believe alternating or combining AZQ and BCNU should be rewarding. The principal toxicity of AZQ is myelosuppression.

Original language	English (US)
Pages (from-to)	309-314
Number of pages	6
Journal	Journal of neuro-oncology
Volume	5
Issue number	4
DOIs	https://doi.org/10.1007/BF00148387
State	Published - Dec 1987

Keywords

AZQ
chemotherapy
glioma
radiation therapy

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/BF00148387

Cite this

@article{40b346cbdf8745569cf3191d4baeeae8,

title = "Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors",

abstract = "Ninety-three patients with primary intracranial brain tumors recurrent after cerebral irradiation were treated with aziridinylbenzoquinone (AZQ; Diaziquone). Twenty-four (26%) had tumor regression lasting a median of 9.2 months. Prior chemotherapy was not significantly associated with tumor regression but was associated with survival (median 7.3 months no prior chemotherapy versus 4.7 months with prior chemotherapy; logrank p = 0.03). AZQ demonstrated anti-tumor activity in a wide variety of primary intracranial neoplasms recurrent after radiation therapy and deserves study in patients at the time of diagnosis. We believe alternating or combining AZQ and BCNU should be rewarding. The principal toxicity of AZQ is myelosuppression.",

keywords = "AZQ, chemotherapy, glioma, radiation therapy",

author = "Eagan, {Robert T.} and Dinapoli, {Robert P.} and Cascino, {Terrence L.} and Bernd Scheithauer and O'Neill, {Brian P.} and O'Fallon, {Judith R.}",

year = "1987",

month = dec,

doi = "10.1007/BF00148387",

language = "English (US)",

volume = "5",

pages = "309--314",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors

AU - Eagan, Robert T.

AU - Dinapoli, Robert P.

AU - Cascino, Terrence L.

AU - Scheithauer, Bernd

AU - O'Neill, Brian P.

AU - O'Fallon, Judith R.

PY - 1987/12

Y1 - 1987/12

N2 - Ninety-three patients with primary intracranial brain tumors recurrent after cerebral irradiation were treated with aziridinylbenzoquinone (AZQ; Diaziquone). Twenty-four (26%) had tumor regression lasting a median of 9.2 months. Prior chemotherapy was not significantly associated with tumor regression but was associated with survival (median 7.3 months no prior chemotherapy versus 4.7 months with prior chemotherapy; logrank p = 0.03). AZQ demonstrated anti-tumor activity in a wide variety of primary intracranial neoplasms recurrent after radiation therapy and deserves study in patients at the time of diagnosis. We believe alternating or combining AZQ and BCNU should be rewarding. The principal toxicity of AZQ is myelosuppression.

AB - Ninety-three patients with primary intracranial brain tumors recurrent after cerebral irradiation were treated with aziridinylbenzoquinone (AZQ; Diaziquone). Twenty-four (26%) had tumor regression lasting a median of 9.2 months. Prior chemotherapy was not significantly associated with tumor regression but was associated with survival (median 7.3 months no prior chemotherapy versus 4.7 months with prior chemotherapy; logrank p = 0.03). AZQ demonstrated anti-tumor activity in a wide variety of primary intracranial neoplasms recurrent after radiation therapy and deserves study in patients at the time of diagnosis. We believe alternating or combining AZQ and BCNU should be rewarding. The principal toxicity of AZQ is myelosuppression.

KW - AZQ

KW - chemotherapy

KW - glioma

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0023610057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023610057&partnerID=8YFLogxK

U2 - 10.1007/BF00148387

DO - 10.1007/BF00148387

M3 - Article

C2 - 3440875

AN - SCOPUS:0023610057

SN - 0167-594X

VL - 5

SP - 309

EP - 314

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 4

ER -

Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this